Benjamin Burnett
Stock Analyst at Wells Fargo
(3.48)
# 849
Out of 5,180 analysts
105
Total ratings
45.68%
Success rate
6.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Overweight | $175 → $177 | $153.32 | +15.44% | 4 | Mar 24, 2026 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Overweight | $34 → $30 | $19.22 | +56.09% | 1 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Overweight | $37 → $43 | $30.15 | +42.62% | 4 | Feb 26, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $193 → $202 | $160.50 | +25.86% | 4 | Feb 24, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $27.58 | +26.90% | 3 | Nov 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.13 | +165.49% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $44.34 | +10.51% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $114.77 | +6.30% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $21.90 | +215.07% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $31.45 | +116.22% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $4.4 → $4.6 | $2.22 | +107.21% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $4.32 | +1,231.02% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $3.32 | +653.01% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.42 | +14,291.14% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $13 | $6.62 | +96.37% | 4 | Mar 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $466 → $486 | $588.36 | -17.40% | 3 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $35.18 | +44.97% | 2 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $46 | $27.69 | +66.12% | 2 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $49 → $68 | $55.55 | +22.41% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $10.68 | +87.27% | 2 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $2.37 | +195.36% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $282 → $305 | $276.44 | +10.33% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $86 | $65.64 | +31.02% | 2 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $45 | $19.30 | +133.16% | 1 | Dec 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $9 | $5.05 | +78.22% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $92.71 | -30.97% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $60.78 | +54.66% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.25 | +207.69% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $65.25 | +451.72% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.31 | +5,106.64% | 1 | Jan 6, 2021 |
Insmed
Mar 24, 2026
Maintains: Overweight
Price Target: $175 → $177
Current: $153.32
Upside: +15.44%
Amphastar Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $34 → $30
Current: $19.22
Upside: +56.09%
Alkermes
Feb 26, 2026
Maintains: Overweight
Price Target: $37 → $43
Current: $30.15
Upside: +42.62%
Axsome Therapeutics
Feb 24, 2026
Maintains: Overweight
Price Target: $193 → $202
Current: $160.50
Upside: +25.86%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $27.58
Upside: +26.90%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.13
Upside: +165.49%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $44.34
Upside: +10.51%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $114.77
Upside: +6.30%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $21.90
Upside: +215.07%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $31.45
Upside: +116.22%
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $2.22
Upside: +107.21%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $4.32
Upside: +1,231.02%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $3.32
Upside: +653.01%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.42
Upside: +14,291.14%
Mar 27, 2026
Maintains: Overweight
Price Target: $27 → $13
Current: $6.62
Upside: +96.37%
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $466 → $486
Current: $588.36
Upside: -17.40%
Mar 23, 2026
Maintains: Overweight
Price Target: $44 → $51
Current: $35.18
Upside: +44.97%
Mar 11, 2026
Maintains: Overweight
Price Target: $43 → $46
Current: $27.69
Upside: +66.12%
Mar 10, 2026
Maintains: Overweight
Price Target: $49 → $68
Current: $55.55
Upside: +22.41%
Mar 5, 2026
Maintains: Overweight
Price Target: $23 → $20
Current: $10.68
Upside: +87.27%
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $7
Current: $2.37
Upside: +195.36%
Feb 20, 2026
Maintains: Equal-Weight
Price Target: $282 → $305
Current: $276.44
Upside: +10.33%
Feb 20, 2026
Maintains: Overweight
Price Target: $93 → $86
Current: $65.64
Upside: +31.02%
Dec 30, 2025
Maintains: Overweight
Price Target: $65 → $45
Current: $19.30
Upside: +133.16%
Dec 18, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $5.05
Upside: +78.22%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $92.71
Upside: -30.97%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $60.78
Upside: +54.66%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.25
Upside: +207.69%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $65.25
Upside: +451.72%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.31
Upside: +5,106.64%